{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field 0e9b9592-86e8-4fb7-95af-a9ca0098d6b0 --><h2>What is the prognosis?</h2><!-- end field 0e9b9592-86e8-4fb7-95af-a9ca0098d6b0 -->","summary":"","htmlStringContent":"<!-- begin item 1a837809-8663-4a58-a909-a9ca0098d65c --><!-- begin field afd57d8b-61c0-450c-9c4f-a9ca0098d6b0 --><ul><li><strong>If pulmonary embolism (PE) is left untreated, </strong>the prognosis is poor and <a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/background-information/complications/\">risk of death</a> is high [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>]. </li><li><strong>Following treatment, </strong>some people develop <a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/background-information/complications/\">complications</a>, such as chronic thromboembolic pulmonary hypertension.</li><li><strong>Recurrence of PE</strong> is more frequent in people with an unprovoked PE (as they have <a class=\"topic-reference internal-reference\" href=\"/topics/pulmonary-embolism/background-information/pathophysiology/\">risk factors</a><strong> </strong>that cannot be removed [such as active cancer or thrombophilia]) and after multiple episodes of venous thromboembolism (VTE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>].<ul><li>The risk of recurrence also varies with the time since the first event [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Heit, 2016</a>]:<ul><li>In historical data, the cumulative proportion of people with early recurrence of VTE (deep vein thrombosis [DVT] or PE) was reported as 2%, 6.4%, and 8% at 2 weeks, 3 months, and 6 months after treatment, respectively. However, evidence from more recent, randomized studies indicate that recurrence rates may have dropped and that the rate of recurrence is highest during the first 2 weeks of treatment and declines thereafter [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>].</li><li>The cumulative proportion of people with late recurrence of VTE (after 6 months, and in most cases after discontinuation, of anticoagulation treatment) has been reported as 13% at 1 year, 23% at 5 years, and 30% at 10 years.</li></ul></li><li>The frequency of recurrence does not appear to depend on the clinical presentation of the first event (that is, whether it was a DVT or PE), but recurrent VTE is likely to occur in the same clinical form as the first event [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>].</li></ul></li></ul><!-- end field afd57d8b-61c0-450c-9c4f-a9ca0098d6b0 --><!-- end item 1a837809-8663-4a58-a909-a9ca0098d65c -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}